TherapeuticsMD Inc. (NASDAQ:TXMD) went down by -4.39% from its latest closing price compared to the recent 1-year high of $2.75. The company’s stock price has collected -7.01% of loss in the last five trading sessions. Press Release reported on 01/05/22 that Thinking about buying stock in 9 Meters Biopharma, TherapeuticsMD, Cameco Corp, Nikola Corp, or Comstock Mining?
Is It Worth Investing in TherapeuticsMD Inc. (NASDAQ :TXMD) Right Now?
Plus, the 36-month beta value for TXMD is at 1.70. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for TherapeuticsMD Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $4.33, which is $3.96 above the current price. TXMD currently public float of 395.39M and currently shorts hold a 6.71% ratio of that float. Today, the average trading volume of TXMD was 5.87M shares.
TXMD’s Market Performance
TXMD stocks went down by -7.01% for the week, with a monthly drop of -21.53% and a quarterly performance of -47.01%, while its annual performance rate touched -74.23%. The volatility ratio for the week stands at 16.21% while the volatility levels for the past 30 days are set at 9.42% for TherapeuticsMD Inc.. The simple moving average for the period of the last 20 days is -8.72% for TXMD stocks with a simple moving average of -59.08% for the last 200 days.
TXMD Trading at -30.49% from the 50-Day Moving Average
After a stumble in the market that brought TXMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.69% of loss for the given period.
Volatility was left at 9.42%, however, over the last 30 days, the volatility rate increased by 16.21%, as shares sank -18.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.01% lower at present.
During the last 5 trading sessions, TXMD fell by -7.01%, which changed the moving average for the period of 200-days by -73.48% in comparison to the 20-day moving average, which settled at $0.3967. In addition, TherapeuticsMD Inc. saw 2.95% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at TXMD starting from Donegan Michael C, who sale 29,790 shares at the price of $0.54 back on Nov 30. After this action, Donegan Michael C now owns 99,368 shares of TherapeuticsMD Inc., valued at $15,947 using the latest closing price.
Collins Cooper C., the Director of TherapeuticsMD Inc., purchase 1,000,000 shares at $0.58 during a trade that took place back on Nov 18, which means that Collins Cooper C. is holding 2,236,864 shares at $578,500 based on the most recent closing price.
Stock Fundamentals for TXMD
Current profitability levels for the company are sitting at:
- -239.76 for the present operating margin
- +73.77 for the gross margin
The net margin for TherapeuticsMD Inc. stands at -282.90. The total capital return value is set at -91.74, while invested capital returns managed to touch -109.45. Equity return is now at value 286.00, with -81.60 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 3.64, with the company’s debt to enterprise value settled at 0.50. The receivables turnover for the company is 2.29 and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.17.